Teva Pharmaceutical Industries Limited (TEVA) Receives Daily News Sentiment Score of 0.16
News headlines about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5287333653327 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern’s scoring:
- Active Biotech’s partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting (nasdaq.com)
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 – TEVA (finance.yahoo.com)
- APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm (finance.yahoo.com)
- TEVA Reminder Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd. (finance.yahoo.com)
- INVESTOR ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited (finance.yahoo.com)
Several brokerages have recently weighed in on TEVA. Jefferies Group LLC reaffirmed a “hold” rating and issued a $26.00 target price (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday. Deutsche Bank AG reaffirmed a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Sanford C. Bernstein downgraded Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $42.00 to $28.00 in a research report on Friday, August 4th. Finally, Maxim Group reaffirmed a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Five equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $27.63.
Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 14.93 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $14.30 and a 12-month high of $44.42. The stock’s 50 day moving average price is $16.59 and its 200 day moving average price is $25.64. The company’s market capitalization is $15.17 billion.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the firm posted $1.25 EPS. The business’s revenue was up 12.9% on a year-over-year basis. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.24 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Receives Daily News Sentiment Score of 0.16” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/10/20/teva-pharmaceutical-industries-limited-teva-receives-daily-news-sentiment-score-of-0-16.html.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.